Related references
Note: Only part of the references are listed.Drug-resistant MS spasticity treatment with Sativex® add-on and driving ability
M. Freidel et al.
ACTA NEUROLOGICA SCANDINAVICA (2015)
Spasticity in patients with multiple sclerosis - clinical characteristics, treatment and quality of life
P. Flachenecker et al.
ACTA NEUROLOGICA SCANDINAVICA (2014)
Costs and quality of life in multiple sclerosis patients with spasticity
J. Svensson et al.
ACTA NEUROLOGICA SCANDINAVICA (2014)
Delta-9-Tetrahydrocannabinol/Cannabidiol (Sativex®): A Review of Its Use in Patients with Moderate to Severe Spasticity Due to Multiple Sclerosis
Yahiya Y. Syed et al.
DRUGS (2014)
A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment
M. Serpell et al.
EUROPEAN JOURNAL OF PAIN (2014)
Long-Term Effectiveness and Safety of Nabiximols (Tetrahydrocannabinol/Cannabidiol Oromucosal Spray) in Clinical Practice
Peter Flachenecker et al.
EUROPEAN NEUROLOGY (2014)
Advances in the Management of MS Spasticity: Recent Observational Studies
Oscar Fernandez
EUROPEAN NEUROLOGY (2014)
Nabiximols (THC/CBD Oromucosal Spray, Sativex (R)) in Clinical Practice - Results of a Multicenter, Non-Interventional Study (MOVE 2) in Patients with Multiple Sclerosis Spasticity
Peter Flachenecker et al.
EUROPEAN NEUROLOGY (2014)
Evaluation of the tolerability and efficacy of Sativex in multiple sclerosis
Irene Moreno Torres et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2014)
Linguistic and psychometric validation of the MSSS-88 questionnaire for patients with multiple sclerosis and spasticity in Germany
Thomas Henze et al.
HEALTH AND QUALITY OF LIFE OUTCOMES (2014)
Clinical experience with THC: CBD oromucosal spray in patients with multiple sclerosis-related spasticity
Juergen Koehler et al.
INTERNATIONAL JOURNAL OF NEUROSCIENCE (2014)
ATLAS OF MULTIPLE SCLEROSIS 2013: A GROWING GLOBAL PROBLEM WITH WIDESPREAD INEQUITY
Paul Browne et al.
NEUROLOGY (2014)
Impact of Sativex® on quality of life and activities of daily living in patients with multiple sclerosis spasticity
Rafael Arroyo et al.
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH (2014)
Burden of disease in multiple sclerosis patients with spasticity in Germany: mobility improvement study (Move I)
Uwe K. Zettl et al.
EUROPEAN JOURNAL OF HEALTH ECONOMICS (2014)
MObility ImproVEment with spasticity in multiple sclerosis in Europe: the MOVE 1 EU study
Patrick Vermersch
NEURODEGENERATIVE DISEASE MANAGEMENT (2014)
Driving performance in persons with mild to moderate symptoms of multiple sclerosis
Hannes Devos et al.
DISABILITY AND REHABILITATION (2013)
A phase I study to assess the effect of food on the single dose bioavailability of the THC/CBD oromucosal spray
C. G. Stott et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2013)
A phase I study to assess the single and multiple dose pharmacokinetics of THC/CBD oromucosal spray
C. G. Stott et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Endocannabinoid system modulator use in everyday clinical practice in the UK and Spain
Antonio Garcia-Merino
EXPERT REVIEW OF NEUROTHERAPEUTICS (2013)
A new multiple sclerosis spasticity treatment option: effect in everyday clinical practice and cost-effectiveness in Germany
Peter Flachenecker
EXPERT REVIEW OF NEUROTHERAPEUTICS (2013)
Spasticity in multiple sclerosis: results of a patient survey
C. Oreja-Guevara et al.
INTERNATIONAL JOURNAL OF NEUROSCIENCE (2013)
Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis
Michael G. Serpell et al.
JOURNAL OF NEUROLOGY (2013)
An Open-Label Extension Study to Investigate the Long-Term Safety and Tolerability of THC/CBD Oromucosal Spray and Oromucosal THC Spray in Patients With Terminal Cancer-Related Pain Refractory to Strong Opioid Analgesics
Jeremy R. Johnson et al.
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT (2013)
A Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers
Colin Stott et al.
SPRINGERPLUS (2013)
Immune-mediated CNS diseases: A review on nosological classification and clinical features
Uwe K. Zettl et al.
AUTOIMMUNITY REVIEWS (2012)
Troublesome Symptoms in Cancer Survivors: Fatigue, Insomnia, Neuropathy, and Pain
Deirdre R. Pachman et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
The Unique Features of Traumatic Brain Injury in Children. Review of the Characteristics of the Pediatric Skull and Brain, Mechanisms of Trauma, Patterns of Injury, Complications and Their Imaging Findings-Part 1
Pedro S. Pinto et al.
JOURNAL OF NEUROIMAGING (2012)
Nabiximols for Opioid-Treated Cancer Patients With Poorly-Controlled Chronic Pain: A Randomized, Placebo-Controlled, Graded-Dose Trial
Russell K. Portenoy et al.
JOURNAL OF PAIN (2012)
A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex® (nabiximols)
W. Notcutt et al.
MULTIPLE SCLEROSIS JOURNAL (2012)
Sativex® in multiple sclerosis spasticity: a cost-effectiveness model
John Slof et al.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2012)
Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticity
Verena Isabell Leussink et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2012)
Plasma Cannabinoid Pharmacokinetics following Controlled Oral Delta(9)-Tetrahydrocannabinol and Oromucosal Cannabis Extract Administration
Erin L. Karschner et al.
CLINICAL CHEMISTRY (2011)
A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis
A. Novotna et al.
EUROPEAN JOURNAL OF NEUROLOGY (2011)
Abuse potential and psychoactive effects of δ-9-tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine
Philip Robson
EXPERT OPINION ON DRUG SAFETY (2011)
THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis
Jaume Sastre-Garriga et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2011)
Impact of responder definition on the enriched enrollment randomized withdrawal trial design for establishing proof of concept in neuropathic pain
David J. Hewitt et al.
PAIN (2011)
Rehabilitation in practice Spasticity management
V. L. Stevenson
CLINICAL REHABILITATION (2010)
Stop using the Ashworth scale for the assessment of spasticity
Katharina S. Sunnerhagen
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2010)
Stop using the Ashworth Scale for the assessment of spasticity
J. F. M. Fleuren et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2010)
Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Efficacy, Safety, and Tolerability of THC:CBD Extract and THC Extract in Patients with Intractable Cancer-Related Pain
Jeremy R. Johnson et al.
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT (2010)
Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis
Derick T. Wade et al.
MULTIPLE SCLEROSIS JOURNAL (2010)
A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis
C. Collin et al.
NEUROLOGICAL RESEARCH (2010)
Contribution of impaired mobility and general symptoms to the burden of multiple sclerosis
Howard L. Zwibel
ADVANCES IN THERAPY (2009)
Emerging strategies for exploiting cannabinoid receptor agonists as medicines
Roger G. Pertwee
BRITISH JOURNAL OF PHARMACOLOGY (2009)
Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb
Angelo A. Izzo et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2009)
The contribution of cognition and spasticity to driving performance in multiple sclerosis
Thomas A. Marcotte et al.
ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION (2008)
Validity, reliability, and clinical importance of change in a 0-10 numeric rating scale measure of spasticity: A post hoc analysis of a randomized, double-blind, placebo-controlled trial
John T. Farrar et al.
CLINICAL THERAPEUTICS (2008)
Managing neuropathic pain with Sativex®:: a review of its pros and cons
Jordi Perez et al.
EXPERT OPINION ON PHARMACOTHERAPY (2008)
National MS registries
Peter Flachenecker et al.
JOURNAL OF NEUROLOGY (2008)
Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptors
G. Pryce et al.
BRITISH JOURNAL OF PHARMACOLOGY (2007)
Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis
C. Collin et al.
EUROPEAN JOURNAL OF NEUROLOGY (2007)
Endocannabinoids and the regulation of their levels in health and disease
Vincenzo Di Marzo et al.
CURRENT OPINION IN LIPIDOLOGY (2007)
Cannabinoid pharmacology: the first 66 years
RG Pertwee
BRITISH JOURNAL OF PHARMACOLOGY (2006)
Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis
D. T. Wade et al.
MULTIPLE SCLEROSIS JOURNAL (2006)
Combined cannabinoid therapy via an oromucosal spray
Jordi Perez
DRUGS OF TODAY (2006)
Managing the symptoms of multiple sclerosis: A multimodal approach
Heidi J. Crayton et al.
CLINICAL THERAPEUTICS (2006)
Botulinum toxin in patients with multiple sclerosis
C Kabus et al.
JOURNAL OF NEUROLOGY (2006)
A tale of two cannabinoids: The therapeutic rationale for combining tetrahydrocannabinol and cannabidiol
E Russo et al.
MEDICAL HYPOTHESES (2006)
Symptomatic treatment of multiple sclerosis
T. Henze et al.
EUROPEAN NEUROLOGY (2006)
Getting the measure of spasticity in multiple sclerosis: the Multiple Sclerosis Spasticity Scale (MSSS-88)
JC Hobart et al.
BRAIN (2006)
Clinical scales for the assessment of spasticity, associated phenomena, and function: a systematic review of the literature
T Platz et al.
DISABILITY AND REHABILITATION (2005)
Neurophysiological methods for the assessment of spasticity: The Hoffmann reflex, the tendon reflex, and the stretch reflex
GE Voerman et al.
DISABILITY AND REHABILITATION (2005)
Biomechanical approaches applied to the lower and upper limb for the measurement of spasticity: A systematic review of the literature
DE Wood et al.
DISABILITY AND REHABILITATION (2005)
Causal association between cannabis and psychosis: examination of the evidence
L Arseneault et al.
BRITISH JOURNAL OF PSYCHIATRY (2004)
Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients
DT Wade et al.
MULTIPLE SCLEROSIS (2004)
Prevalence and treatment of spasticity reported by multiple sclerosis patients
MA Rizzo et al.
MULTIPLE SCLEROSIS (2004)
Spasticity in multiple sclerosis
MP Barnes et al.
NEUROREHABILITATION AND NEURAL REPAIR (2003)
Cognitive functioning of long-term heavy cannabis users seeking treatment
N Solowij et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2002)
Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide
T Bisogno et al.
BRITISH JOURNAL OF PHARMACOLOGY (2001)
Neuropharmacology and therapeutic potential of cannabinoids
RG Pertwee
ADDICTION BIOLOGY (2000)
Share Paper
